Protocol Ledger

NCT04988386 · Phase III · ACTIVE NOT RECRUITING

Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants

Interventional Phase III clinical trial protocol NCT04988386 sponsored by Eidos Therapeutics, a BridgeBio company in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-10-27 Enrollment: 389 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04988386
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)389 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04988386
Protocol FieldVerified Registry Value
NCT IdentifierNCT04988386
Consolidated Lead SponsorEidos Therapeutics, a BridgeBio company
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment389 participants (ACTUAL)
Registered Start Date2021-10-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI